Table 3.
No | A | B | C | D | EE% |
---|---|---|---|---|---|
1 | 1 | 1 | 1 | 1 | 40.68 |
2 | 1 | 2 | 2 | 2 | 56.50 |
3 | 1 | 3 | 3 | 3 | 67.73 |
4 | 2 | 1 | 2 | 3 | 65.80 |
5 | 2 | 2 | 3 | 1 | 59.57 |
6 | 2 | 3 | 1 | 2 | 53.14 |
7 | 3 | 1 | 3 | 2 | 78.22 |
8 | 3 | 2 | 1 | 3 | 66.11 |
9 | 3 | 3 | 2 | 1 | 60.41 |
54.970 | 61.567 | 53.310 | 53.553 | – | |
59.503 | 60.727 | 60.903 | 62.620 | – | |
68.247 | 60.427 | 68.507 | 66.547 | – | |
R | 13.277 | 1.140 | 15.197 | 12.994 | – |
Notes: Factor A, emulsifying temperature; factor B, the volume ratio of the oil phase to the inner water phase; factor C, the mass ratio of drug to lipids; and factor D, the mass ratio of F68 to T80. EE was expressed as mean (n=3).
Abbreviations: NRG, naringenin; SLNs, solid lipid nanoparticles; EE, encapsulation efficiency.